Phase 2 Study of TLK286 in Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2004-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness of TLK286 in treatment of metastatic breast cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Telik

Criteria

Inclusion Criteria:

• Histologic diagnosis of breast cancer

• Metastatic disease

• Measurable or evaluable disease

• No prior chemotherapy regimens

• Age at least 18 years

• Adequate liver and kidney function

• Adequate bone marrow function

Exclusion Criteria:

• Pregnant or lactating women

• Unstable medical conditions

• Chemotherapy within 14 days of TLK286

• Radiation therapy within 14 days of TLK286

• Hormonal therapy within 14 days of TLK286

• Immunotherapy within 14 days of TLK286

• CNS metastasis unless controlled by treatment